Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01081015 · ClinicalTrials.gov registry record

Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry

A clinical trial, sponsored by Celgene.

Completed
Registry status
1,494
Enrollment target

NCT01081015 is a clinical trial that has completed, run by Celgene. The registered enrollment target is 1,494 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01081015 has completed, sponsored by Celgene.

COMPLETED
Registry status
1,494 participants
Enrollment target

Study Summary

The purpose of the Connect™ Chronic Lymphocytic Leukemia (CLL) Disease Registry is to explore the history and real world management of patients diagnosed with CLL, provide insight into the management of CLL, and evaluate the effectiveness of first, second and subsequent therapeutic strategies employed in both the community and academic settings.

Trial Details

FieldValue
Enrollment Target 1,494 participants
Start Date 2010-03-19
Est. Completion 2017-12-31

Sponsor

Celgene

308 total trials

What the Registry Record Tells You About NCT01081015

The ClinicalTrials.gov registry entry for NCT01081015 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,494 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Celgene, which has 308 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 0 interventions.

NCT01081015 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01081015 about?

NCT01081015 is a clinical study titled "Connect™ CLL: The Chronic Lymphocytic Leukemia Disease Registry". The purpose of the Connect™ Chronic Lymphocytic Leukemia (CLL) Disease Registry is to explore the history and real world management of patients diagnosed with CLL, provide insight into the management of CLL, and evaluate the effectiveness of first, second and subsequent therapeutic strategies employ...

What is the current status of trial NCT01081015?

This trial is currently completed. The enrollment target is 1,494 participants. The study started on 2010-03-19. Estimated completion is 2017-12-31.

Who is sponsoring clinical trial NCT01081015?

This trial is sponsored by Celgene, which has 308 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.